Maple Capital Management’s AstraZeneca AZN Stock Holding History

Maple Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,300	Closed	-$210K	–	124
2015 Q2	$210K	Hold	3,300	–	–	0.07%	117
2015 Q1	$226K	Sell	3,300 -3,000	-48%	-$208K	0.08%	117
2014 Q4	$443K	Hold	6,300	–	–	0.16%	84
2014 Q3	$450K	Hold	6,300	–	–	0.17%	78
2014 Q2	$468K	Buy	6,300 +500	+9%	+$36.1K	0.17%	80
2014 Q1	$376K	Hold	5,800	–	–	0.15%	90
2013 Q4	$344K	Buy	5,800 +625	+12%	+$34K	0.14%	99
2013 Q3	$269K	Buy	5,175 +600	+13%	+$30.1K	0.12%	103
2013 Q2	$216K	Buy	+4,575	New	+$233K	0.1%	113

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Maple Capital Management's AZN Position: Q3 2015 in Review

Maple Capital Management sold out of AstraZeneca (AZN) in Q3 2015, closing a stake of 3,300 shares — an estimated $210K sold.

Maple Capital Management first reported a position in AZN in Q2 2013 and held it in 9 quarters. The position peaked at $468K in Q2 2014. 371 funds tracked by Wall St. Rank hold AZN as of Q3 2015.

Maple Capital Management reported no remaining AstraZeneca position as of Q3 2015 after selling out during the quarter.
Maple Capital Management sold 3,300 AstraZeneca shares in Q3 2015, an estimated $210K.
Maple Capital Management first reported a position in AstraZeneca in Q2 2013 and held it in 9 quarters.
Maple Capital Management's AstraZeneca position peaked at $468K in Q2 2014.
371 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2015.

Based on Maple Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.